1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Astellas Beats Rivals To Japan HIF-PHI Market As Roxadustat Launched

 
• By Ian Haydock

Astellas becomes first to market in Japan in new class of oral anemia drugs, beating multiple rivals in a sector set to see strong growth but also fierce competition.

Rocket takes off from the hand of the businessman. Concept of start up.
Roxadustat Launches First Salvo In Japan HIF-PHI Battle • Source: Shutterstock

Following an approval in September, Astellas Pharma Inc. has launched in Japan the novel oral anemia drug roxadustat, making it the first in the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) class to reach the market in the country.

The first-in-class molecule, discovered by and licensed from FibroGen Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

More from Focus On Asia